Skip to main content
Fig. 1 | BMC Cancer

Fig. 1

From: Real-world efficacy and safety of two doses of cabazitaxel (20 or 25 mg/m2) in patients with castration-resistant prostate cancer: results of a Japanese post-marketing surveillance study

Fig. 1

Patient disposition. *Patients who satisfied the following criteria: treatment with docetaxel before cabazitaxel; administration of prednisolone with cabazitaxel; and the cabazitaxel dose was not escalated above the initial dose during the treatment period. †Patients were matched using propensity scores on 17 factors: age, body surface area, duration of disease, Gleason score, T classification, N classification, M classification, ECOG PS, PSA, medical history, complications, curative intent focal therapy, palliative radiation therapy, switch from docetaxel, number of docetaxel treatment cycles, reason for discontinuation of docetaxel, and previous treatment with enzalutamide or abiraterone. C20, 20 mg/m2 cabazitaxel; C25, 25 mg/m2 cabazitaxel

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us